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Obesity is defined as the abnormal or   excessive 
accumulation of fat that presents a risk to 
health. Globally there are more than 300 
million adults who are obese [World Health 
Organization (WHO) 2010] and 42 million 
children who are overweight (WHO 2010). 
Obesity is caused by a complex interplay of 
multiple factors (environmental and genetic)
that can be ascribed to an imbalance in energy 
homeostasis under the control of the central 
nervous system. Although evidence for a role 
of the hypothalamus in obesity was derived 
from lesion experiments conducted > 50 years 
ago (Kennedy 1953), many gaps still remain 
in our knowledge of hypothalamic fat regu-
lation. Recent evidence has implicated obe-
sity in conferring a greater susceptibility to 
the adverse effects of environmental exposure 
(Chung and Yoon 2008). Conversely, there 
is evidence to suggest that the neuronal dam-
age caused by environmental exposure can 
induce obesity (Edwards and Myers 2008). In 
the past, obesity as a result of environmental 
exposure was largely overlooked because of 
the commonly held belief that increases in 
obesity after the industrial revolution were due 
solely to changes in eating habits. However, 
concurrent with the industrial revolution was 
the mobilization of and increased exposure 
to heavy metals such as lead and mercury 
(Hg). To our knowledge, no epidemiological 
studies have provided a direct link between 
heavy metal exposure and obesity in humans. 
However, circumstantial evidence was offered 
by Turunen et al. (2008) who identified a 
correlation between high fish consumption, 
increased concentrations of environ  mental 
toxins in serum, and increased obesity. 
Furthermore, epidemiological evidence has 
suggested that obesity increases the suscepti-
bility of fine metal particulate–induced cardio-
vascular effects (Chen et al. 2007). Because the 
intricate dissection of the underlying mecha-
nisms within complex mammalian systems 
can be challenging, scientists have found that 
using simple eukaryotic invertebrate models, 
such as the nematode Caenorhabditis elegans, 
have proved to be tangible alternatives (Lant 
and Storey 2010).
C. elegans—general concepts. C. elegans 
is a small, free-living, soil-dwelling nematode 
that requires a humid environment, atmo-
spheric oxygen, and bacteria as a food source 
(Byerly et al. 1976). C. elegans is predomi-
nantly a self-fertilizing hermaphrodite (and 
thus in essence clonal), has a short life span of 
approximately 18–20 days, a rapid generation 
time (3 days at 22°C), and a large brood size 
(around 300 progeny per hermaphrodite). Its 
transparency allows the noninvasive visualiza-
tion of cellular structures and green fluorescent 
protein (GFP)–tagged transcripts and proteins, 
even within single neurons. All neurons and 
synapses develop stereotypically and have been 
mapped by 3-dimensional reconstruction of 
transmission electron microscopy (TEM) serial 
sections (White et al. 1986). Furthermore, the 
genome of C. elegans has been fully sequenced 
and is highly conserved with that of mammals 
(60–80% homology) (C. elegans Sequencing 
Consortium 1998). Because of the detailed 
knowledge of its genomic architecture and the 
ease of genetic manipulation, scientists have 
generated thousands of knockout alleles and 
transgenic strains that has permitted detailed 
analyses of mechanistic neurotoxicology.
The nervous system is the most complex 
organ in C. elegans. The hermaphrodite com-
prises 302 nerve cells and 56 epithelioglial 
cells, which together equate to 37% of all 
somatic cells (Bargmann 1998). Nerve cells 
are concentrated in the circum-pharyngeal 
nerve ring in the ventral nerve cord and in 
the tail, with most of the sensory neurons 
located in the head region. A male C. elegans 
(a rare sex, with a frequency of 0.5%) has 
89 additional neurons, most of which are 
posterior sensory and motor neurons (Sulston 
and Horvitz 1977; Sulston et al. 1980) that 
are implicated in male mating behavior 
(Whittaker and Sternberg 2009). The worm 
contains neurotransmitters inherent in the 
mammalian nervous system, including sero-
tonin, dopamine (DA), γ-aminobutyric acid 
(GABA), glutamate, and acetylcholine, as 
well as numerous neuropeptides (Bargmann 
1998). Neurotransmitter-specific transport-
ers (membrane and vesicular) and receptors 
(including G-protein coupled) are also highly 
conserved with their mammalian counterparts 
(Bargmann 1998). The C. elegans nervous sys-
tem is responsible for the control of all basic 
functions in the worm, and it regulates devel-
opment, feeding, movement, metabolism, and 
reproduction (Chatterjee and Sinha 2008; 
Rankin 2002). Accordingly, alterations in any 
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Ba c k g r o u n d: A common link has been exposed, namely, that metal exposure plays a role in obesity 
and in Parkinson’s disease (PD). This link may help to elucidate mechanisms of neurotoxicity.
oB j e c t i v e: We reviewed the utility of the nematode, Caenorhabditis elegans, as a model organism to 
study neurodegeneration in obesity and Parkinson’s disease (PD), with an emphasis on the neuro­
transmitter, dopamine (DA).
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or “Parkinson’s disease.” We reviewed the identified studies, including others cited therein, to sum­
marize the current evidence of neurodegeneration in obesity and PD, with an emphasis on studies 
carried out in C. elegans and environmental toxins in the etiology of both diseases.
da t a e x t r a c t i o n a n d d a t a synthesis: Heavy metals and DA have both been linked to diet­
induced obesity, which has led to the notion that the mechanism of environmentally induced 
neurodegeneration in PD may also apply to obesity. C. elegans has been instrumental in expanding 
our mechanism­based knowledge of PD, and this species is emerging as a good model of obesity. 
With well­established toxicity and neurogenetic assays, it is now feasible to explore the putative link 
between metal­ and chemical­induced neurodegeneration.
co n c l u s i o n s: One side effect of an aging population is an increase in the prevalence of obesity, 
meta  bolic disorders, and neurodegenerative orders, diseases that are likely to co­occur. Environmental 
toxins, especially heavy metals, may prove to be a previously neglected part of the puzzle.
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neurotransmitter system cause disturbances 
in specific functions commensurate with the 
affected type of neuron. Consequently, C. ele-
gans is well recognized for its utility as an 
animal model for deciphering mechanisms of 
neurodegeneration.
This review aims to provide an authorita-
tive overview demonstrating how C. elegans 
can be exploited as a model to study obe-
sity and neurodegeneration, with a particular 
focus on environmental toxins and their role 
within the dopaminergic system. First, we 
describe the use of C. elegans as a model of 
obesity and the parallels to mammalian feed-
ing and fat regulation. Next, we highlight 
the evidence of neurodegeneration in obesity 
and the impact of obesity on neurodegenera-
tion. We then examine how the nematode has 
been used to study neurodegeneration in the 
Parkinson’s disease (PD) model using DA as 
the main neurotransmitter. Finally, we inves-
tigate the effects of heavy metals and chemi-
cals on neuronal degeneration.
C. elegans—the plus-size model. Although 
the nematode has long served as a model 
organism for a range of diseases, only recently 
has this species been considered relevant 
to obesity research. In 2003, Ashrafi et al. 
(2003) and McKay et al. (2003) indepen-
dently described C. elegans as a useful model 
for gaining insights into the genetics of fat 
regulation. The advantage of having the fully 
sequenced C. elegans genome has permitted 
the identification of numerous genes encod-
ing regulators of fat storage and transport 
as well as neuroendocrine regulators of fat 
and food-related behaviors, many of which 
have mammalian homologs (Mullaney and 
Ashrafi 2009). The core metabolic processes 
governing fat regulation are highly conserved, 
as is the lipid content of nematodes, which 
occurs primarily in the form of triglycerides, 
the major form of fat in foods (Ashrafi 2007; 
Burnell et al. 2005; Holt and Riddle 2003; 
McKay et al. 2003; Van Gilst et al. 2005; 
Wang and Kim 2003). As in mammals, fat 
levels in the nematode increase as a result of 
excess calories from sugars such as fructose 
and glucose, and the mechanism of this fat 
accumulation and utilization is regulated by 
a variety of well-preserved, albeit complex, 
transcriptional, translational, and posttrans-
lational regulatory systems (Nomura et al. 
2009) (Figure 1).
Despite these overwhelming analogies, 
there are some differences in worm fat regula-
tion that arguably could be considered dis-
advantages. However, when treated correctly, 
these differences can be powerful tools in 
unraveling unique aspects of fat metabolism. 
For example, C. elegans are able to synthesize 
polyunsaturated fatty acids (PUFAs), whereas 
mammals must obtain these fats from their 
diet as essential fatty acids. This difference 
renders it possible to easily examine the roles 
of PUFAs through the use of genetic deletion 
techniques and separately from the complex 
signaling pathways activated by eicosanoids 
(derivatives of 20-carbon PUFAs involved in 
many processes, particularly the inflammatory 
response) in pathways not conserved in the 
nematode (Marza and Lesa 2006). Another 
striking difference between C. elegans and 
mammals is that the intestinal cells of worms 
serve as sites both of fat storage and metabo-
lism, whereas mammals have dedicated adi-
pocytes that store fat. In mammals, leptin 
secretion by adipocytes increases in response 
to excessive energy intake and acts on both 
appetite and peripheral tissues (Halaas et al. 
1995; Shimabukuro et al. 1997). The lack of 
adipocytes and leptin in worms removes one 
of the complex layers involved in the central-
ized control of fat metabolism, thus making it 
easier to reveal the other conserved and under-
lying mechanisms of control. In addition, it 
has recently been demonstrated that Nile red 
staining of fat, a technique used to stain live 
worms and to ascribe a fat regulation role to 
> 400 genes, does not stain the major lipid 
stores in the worm (Ashrafi 2007; O’Rourke 
et al. 2009). Rather, the Nile red technique 
stains fats stored in lysosomal vesicles. It is 
therefore not representative of fixative stain-
ing techniques such as Sudan black and Oil 
Red O, which better represent results from 
biochemical analysis methods such as gas 
chromatography-mass spectrometry or visuali-
zation using coherent anti-stokes Raman 
scattering (Hellerer et al. 2007; O’Rourke 
et al. 2009). Although lipid accumulation 
in lysosomes is an important part of lipid 
metabolism and has a role in the pathology of 
diseases such as Tay Sachs and Niemann Pick, 
the data can be mis  leading if used incorrectly, 
that is, assuming that lipid accumulation is 
a measure of major fat storage, which can 
easily lead to numerous mis  interpretations. 
Nonetheless, such lipid storage may be more 
important in worms because of the lack of 
adipocytes; hence, lysosomal staining should 
not be overlooked.
Neuronal regulation of feeding. The nema-
tode feeds continuously, but the feeding rate 
is not passive. Rather, it is modulated by food 
availability that is detected by the central ner-
vous system. Similar to mammalian regulation 
of feeding, serotonin signaling in the worm 
plays an integral, albeit paradoxical, role. In 
mammals, both the rates of feeding and fat 
Figure 1. Neuronal control of feeding behavior and fat regulation in the nematode. Some of the neurons in 
the head region are exposed to the environment and integrate nutritional signals (olfactory, gustatory, and 
chemosensory) to coordinate numerous peripheral responses such as fat metabolism and reproduction. 
Peripheral sites of fat regulation are also able to feed back to the neurons to promote or inhibit neuro­
endocrine signals in neurons and peripheral sites. Colors of neurons in the nematode are matched to the 
key neurons annotated in the colored boxes. The question mark (1) indicates an unconfirmed hypothetical 
link. ADE indicates the anterior deirid; ADF, ADL, ASE, ASG, ASH, ASI, ASJ, and ASK are chemosensory neu­
rons; AWA, AWB, and AWC are odorsensory neurons; BBS is a neuronally expressed gene associated with 
both adult and childhood obesity; PDE indicates the posterior deirid; and tub-1 is isoform 1 of Tubby protein 
homolog. Adapted from Inglis et al. (2006) and Mak et al. (2006).
AWA, AWB
AWC
ADL, ADF
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Tub-1 and BBS expressed in ciliated neurons regulate metabolism and are associated with serotonin signaling.
Serotonin and tyramine signaling regulates feeding and fat.
Insulin signaling regulates metabolism.
Germline signals regulate insulin signaling.
Dopamine modulates locomotion and feeding proposed to signal a state of hunger.Aitlhadj et al.
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accumulation increase when serotonin levels 
are elevated. However, in C. elegans, increased 
serotonin signaling results in the reduction 
of fat accumulation while counterintuitively 
augmenting the feeding rate (Srinivasan et al. 
2008). Although the ability of serotonin to 
control satiety and fat accumulation by two 
independent pathways is presented as a dis-
tinct feature of nematodes, evidence suggests 
that similar mechanisms also exist in mamma-
lian systems. For example, tubby mutants in 
mice and nematodes (tubby and tub-1, respec-
tively) display adult-onset obesity without 
exhibiting hyperphagia (Coyle et al. 2008; 
Mukhopadhyay et al. 2005). Because there 
is evidence that the Tubby protein can inter-
act with G-coupled receptors, including the 
5-HT2c (serotonin) receptor (Santagata et al. 
2001), it is conceivable that there is a similar 
mechanism of independent fat and feeding 
regulation by serotonin that has yet to be fully 
revealed in mammals. This tubby model of 
obesity is different from that of ob/ob or db/db 
mice, mutant strains that follow the increased 
feeding and increased fat accumulation pat-
tern (Campfield et al. 1995; Trayhurn and 
Fuller 1980). If such distinct mechanisms 
were found to occur in mammals, potential 
therapies that were independent of feeding 
habits could be targeted for further research. 
These therapeutic techniques, if effective, 
could prove to be particularly valuable in the 
treatment of obesity, especially considering 
the poor reputation of appetite-suppressing 
drugs (Williams 2010).
Satiety and hunger play important roles 
and together constitute the cornerstone for 
the prevention and treatment of obesity. 
Behavior reminiscent of satiety and hunger 
has also been identified in C. elegans. Under 
certain conditions, the nematode stops feed-
ing and moving, a behavior termed “quies-
cence.” Because quiescence is dependent on 
food quality, nutritional signals from the 
intestine, and prior feeding history, quies-
cence is thought to indicate a state of satiety 
regulated by cyclic guanosine monophosphate 
and transforming growth factor β (TGF-β) 
(You et al. 2008), pathways whose functions 
in appetite control and metabolism have not 
yet been elucidated in mammals. However, 
TGF-β has also been shown to be elevated 
in the obese mouse models, ob/ob and db/db, 
which display increased feeding and obese 
phenotypes (Samad et al. 1997), thus suggest-
ing a similar role for TGF-β in the appetite 
regulation of mammals.
In C. elegans, serotonin and tyramine 
are believed to act as signals for hunger; the 
latter modulates feeding and is a functional 
counterpart of norepinephrine (Roeder 
2005). Tyramine signaling elicits increased 
food intake in the worm, a behavior normally 
caused by food deprivation. In the worm, as 
well as in mammals, the role of the neuro-
transmitters serotonin and norepinephrine has 
been explored, and targets for therapy have 
been attempted. However, the role of DA has 
only recently emerged in mammals, and few 
studies describe its role in obesity pathways. 
In C. elegans, DA is best known for medi-
ating the slowing of movement that occurs 
when the animal encounters food, a behavior 
termed the “basal slowing response” (Sawin 
et al. 2000). DA is hypothesized to be released 
in response to food, and it acts on motor 
neurons to modu  late the movement of the 
nematode (Chase and Koelle 2007). A recent 
study has shown that increasing DA signal-
ing stimulated movement in daf-2 dauers and 
dauer  like adults, but not in non  dauer animals, 
thus suggesting that the reduction in insulin/
insulin-like growth factor (IGF)-1 signaling 
is able to modulate the response of the ani-
mals to DA (Gaglia and Kenyon 2009). This 
altered response to DA is mediated in part 
by increased DAF-16/FOXO transcriptional 
activity in the nervous system. The notion that 
the insulin/IGF-1 signaling pathway can alter 
the activity of the DA pathway in C. elegans 
is compatible with the emerging idea that, 
in the mammalian brain, hormonal signals 
involved in energy balance, including insulin, 
can affect the DA reward pathway to modu-
late feeding behavior (Figlewicz et al. 2007). 
Food-restricted animals, which have lower 
circulating insulin levels, behave as though 
they have elevated DA signaling. This is analo-
gous to norepinephrine in mammals, which, 
at levels of excess, mimics the perception of 
hunger (Figlewicz et al. 2007; Palmiter 2007). 
However, the mechanism by which insulin 
signaling acts at the cellu  lar level to influence 
DA signaling remains unclear.
Neurodegeneration and obesity—the 
chicken or the egg? Because neuronal control 
is the central component of fat regulation, 
it is logical to assume that the integrity of 
this system (i.e., the functional components 
such as neurons) is of equal importance in 
maintaining energy homeostasis. In higher 
vertebrates, gross abnormalities in the brain 
structure and architecture, particularly in the 
frontal lobe, have been associated with obesity 
(Pannacciulli et al. 2006; Taki et al. 2008; 
Ward et al. 2005). Although it is unlikely 
that obesity is directly responsible for brain 
atrophy, there are several lines of evidence 
in mammals that demonstrate an association 
between increased adiposity and exacerbated 
neurodegeneration resulting from chemical 
induction as well as from Alzheimer’s dis-
ease (Chen and Lipton 2006; Moroz et al. 
2008; Sriram et al. 2002). For example, 
Moroz et al. (2008) found that feeding a 
high-fat diet to mice for 16 weeks caused 
an increase in body weight in conjunction 
with type 2 diabetes (a common comorbidity 
of obesity) and a marginally reduced brain 
weight. Interestingly, however, these find-
ings were associated with significantly 
increased levels of several substrates including 
tau, which is part of the pathology of many 
neuro  degenerative diseases (Moroz et al. 
2008). Another study by Sriram et al. (2002) 
used the neurotoxicant methamphetamine 
(METH), a well-characterized dopaminergic 
neurotoxicant that causes a marked decrease 
in striatal DA, tyrosine hydroxylase (TH), 
and DA transporter binding sites (Deng and 
Cadet 1999; Kogan et al. 1976; Sonsalla et al. 
1989) to mimic some key features associated 
with the pathogenesis of PD. Their data indi-
cated that the neurotoxic effects of METH 
in lean mice (decreased striatal DA and TH 
protein as well as an increase in glial fibrillary 
acidic protein) were exaggerated in the obese 
mice, thus implicating obesity as a risk factor 
for susceptibility to neurotoxic insult (Sriram 
et al. 2002). Furthermore, the administration 
of METH resulted in mortality in ob/ob mice 
but not in their lean littermates. In addition, 
the administration of METH resulted in the 
upregulation of the mitochondrial uncoupling 
protein-2 to a greater extent in the ob/ob mice 
than in the lean mice. This effect is known to 
reduce adenosine-5´-triphosphate (ATP) yield 
and to facilitate oxidative stress and mitochon-
drial dysfunction. In summary, the results 
implicate obesity as a risk factor associated 
with chemical- and possibly disease-induced 
neurodegeneration (Sriram et al. 2002).
Although neurodegeneration can easily   
be visualized in C. elegans by labeling neu-
rons with fluorescent markers such as 
FITC (fluorescein isothiocyanate), DiI 
(1,1´-dioctadecyl-3,3,3´,3´,-tetramethylindo-
carbocyanine perchlorate), DiO (3,3´-diocta-
decyloxa carbocyanine perchlorate), and DiD 
(1,1´-dioctadecyl-3,3,3´,3´-tetramethyl-
indodicarbocyanine perchlorate) (Tong and 
Burglin 2010), the direct role of adiposity on 
neurodegeneration has not been explored to 
date. Nevertheless, many conserved pathways 
relevant to obesity as well as neuronal cell 
death are present in the nematode, such as the 
p38 mitogen-activated protein kinase (Heida 
et al. 2010) and AKT signaling cascades, the 
ubiquitin-proteasome pathway (Doherty 
et al. 2008), and the oxidative stress response 
(Uttara et al. 2009), all of which have been 
found to cause neuronal injuries in the worm 
(Ayyadevara et al. 2008; Gami et al. 2006; 
Grad and Lemire 2004; Inoue et al. 2005; 
Tullet et al. 2008). In addition, it has been 
reported that obese humans and rodents dis-
play increased adipocyte apoptosis; further, 
apoptosis has been implicated in many neuro-
degenerative diseases including PD (Bharathi 
et al. 2006; Hirata 2002; Koh 2001; Ong and 
Farooqui 2005). The PD model for obesity in 
worms exhibits polyQ aggregation, which has An invertebrate model for obesity and Parkinson’s disease
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been found to be toxic to neurons in worms, an 
effect similar to that in mammals. Additionally, 
in worms as in mammals, polyQ aggregation 
has been shown to be mediated by daf-16 and 
the insulin-signaling pathway (another impor-
tant pathway in obesity) (Voisine et al. 2007).
These findings support the notion that 
an environment of obesity aggravates neuro-
degeneration. However, there is evidence to 
suggest that the reverse is also true, that is, 
that neurodegeneration may lead to obesity. 
Examples of this include genes such as Ubb 
and tubby, which are both expressed in cili-
ated neurons. Noben-Trauth et al. (1996) 
and Ryu et al. (2008) found that defects in 
each of these genes lead to adult-onset obe-
sity in mammals. Benzinou et al. (2006) 
found that another neuronally expressed gene, 
BBS, is associated with both adult and child-
hood obesity. Because the neurodegenera-
tion occurs prior to the obese phenotype, it is 
likely that neuronal control of fat regulation is 
disrupted and leads to energy imbalance, thus 
resulting in adult-onset obesity, as opposed to 
the early-onset obesity exhibited by models 
such as ob and db. The worm has homologs 
of these three genes expressed in the ciliated 
neurons. These homologs show altered fat 
accumulation and altered longevity under cer-
tain conditions (Aitlhadj and Stürzenbaum 
2010; Ashrafi et al. 2003; Mukhopadhyay 
et al. 2005; Pan et al. 2005). A partial list of 
neuronally expressed genes associated with 
increased fat accumulation when mutated 
is presented in Table 1. Regardless of the 
direction or initiation of obesity and neuro-
degeneration (cause or consequence), both 
conditions result in altered levels of neuro-
transmitters such as serotonin, DA, and nor-
epinephrine which can cause neurotoxicity 
(e.g., serotonin syndrome), a vicious cycle 
that extends beyond both conditions and has 
far-reaching knock-on effects. The alteration 
of neurotransmitter levels results in disease 
phenotypes in both worms and mammals 
(Donohoe et al. 2006; Hapiak et al. 2009; 
Holson et al. 1994). In addition, the chronic 
elevation of serotonin signaling in the hypo-
thalamus induces peripheral insulin resistance, 
consequently causing obesity in mammals 
(Belsare et al. 2010).
Despite evidence linking obesity to neuro-
degeneration, the relationship between these 
two conditions has become the focus of explor-
ative research only recently; therefore, the 
underlying mechanisms remain unidentified.   
However, the role of the neurotransmitter 
DA is beginning to emerge. The next section 
aims to review our current knowledge regard-
ing neurodegeneration in the PD nema  tode 
model and to demonstrate how this informa-
tion can be used to help unravel the mecha-
nisms underlying the neurodegeneration 
observed in obesity.
C. elegans in Parkinson’s disease. PD is 
characterized by the progressive loss of dop-
aminergic neurons and manifests as muscle 
rigidity, tremors, and bradykinesia. PD affects 
DA-producing neurons in the brain, and the 
central tenet regarding the pathology of this 
disease holds that the loss of these neurons 
induces the symptoms of PD. DA is associated 
with motor activity and feelings of reward. 
However, recent evidence has highlighted 
that norepinephrine neurons also play a role 
in the etiology of PD. Norepinephrine is a 
neurotransmitter that controls attentiveness, 
emotions, sleeping, dreaming, and learning, 
but also acts as a hormone to increase heart 
rate and blood pressure, trigger the release of 
glucose and fatty acids from energy stores, 
and open up the air passages to the lungs. 
Although the precise etiology of the vast 
majority of PD cases remains elusive, it has 
been hypothesized that genetic and environ-
mental factors are the causative denomina-
tors of the observed neuro  degeneration. The 
C. elegans nervous system is limited to a mere 
302 neurons. However, the diversity of classi-
cal neuro  transmitters and neuro  peptides is 
comparable to that of a verte  brate nervous 
system. The worm synthesizes DA and octo-
pamine, the latter of which is a neurotrans-
mitter considered to be an invertebrate 
counterpart to norepinephrine (Roeder 2005). 
Exogenous octopamine inhibits egg laying 
and pharyngeal pumping and acts antagonis-
tically to serotonin, which stimulates pharyn-
geal pumping and egg laying (Horvitz et al. 
1982; Niacaris and Avery 2003). The field of 
research exploring octopamine-driven neuro-
toxicity in C. elegans is still in its infancy, but 
a significant volume of work has focused on 
DA in PD.
Parkinson’s disease genes. Studies with 
C. elegans orthologs of human genes linked 
to familial PD have led to novel insights 
into DAergic neurodegeneration. The worm 
genome encodes genes for Parkin, PARK 9, 
UCHL-1 (ubiquitin carboxy-terminal hydro-
lase L1), DJ-1, NURR1 (NUR-related fac-
tor 1), PINK1 (PTEN-induced kinase 1), 
and LRRK2 (leucine-rich repeat kinase 2), 
but notably lacks α-synuclein (Benedetto 
et al. 2009; Gitler et al. 2009; Hamamichi 
et al. 2008; Sakaguchi-Nakashima et al. 
2007; Samann et al. 2009; Ved et al. 2005). 
α-synuclein is a polypeptide with a propensity 
toward intracellular accumulation into inclu-
sions referred to as Lewy bodies, which have 
been invoked as initiators of PD (Singleton 
et al. 2003). In C. elegans, overexpression of 
human α-synuclein causes significant loss of 
DAergic neurons (Hamamichi et al. 2008; 
Lakso et al. 2003). High-throughput RNAi-
based screening in C. elegans revealed five 
neuroprotective genes that affect α-synuclein 
aggregation. The gene products include an 
ubiquitin-activating E1 enzymelike protein 
and a protein involved in lysosomal trafficking, 
VPS41. Notably, overexpression of VPS41 was 
shown to cause decreased α-synuclein aggrega-
tion and protection from DAergic degener-
ation induced by α-synuclein (Hamamichi 
et al. 2008). Further studies investigating 
the neuroprotective effect of VPS41 against 
α-synuclein–induced DAergic degeneration 
demonstrated that the protein acts by reducing 
cell death, attenuating the apoptotic cascade, 
and reducing the accumulation of detergent-
insoluble, high-molecular-weight forms of 
α-synuclein (Ruan et al. 2010). Interestingly, 
the levels of α-synuclein are also relevant to 
obesity, as increased α-synuclein is reportedly 
consistent with increased leptin and obesity 
(Oort et al. 2008).
Several scientists have demonstrated that 
the genetic modulation of parkin (pdr-1), 
dj-1, pink-1, and lrk-1 (the gene that encodes 
LRRK2) disrupts mitochondrial function 
in C. elegans (Samann et al. 2009; Ved et al. 
2005). This mitochondrial dysfunction is 
believed to play a role in triggering DAergic 
degeneration. For example, Ved et al. (2005) 
showed that the loss of function of dj-1 
caused a decrease in oxygen consumption and 
survival after exposure to rotenone—effects 
that were reverted by antioxidants. Similarly, 
pink-1 knockout resulted in reduced mito-
chondrial cristae length in muscle and neu-
ronal cells and defects in axonal outgrowth 
of a pair of canal-associated neurons, whereas 
lrk-1 (tm1898) mutants displayed an aber-
rant axon pathfinding (Samann et al. 2009). 
Of particular importance, this same study 
demon  strated an antagonistic role of PINK-1 
Table 1. Partial list of neuronally expressed mutant alleles that exhibit increased fat accumulation.
Gene Human ortholog Neuronal expression
rpy-1 Isoform 1 of 43 kDa receptor-associated protein of the synapse DA, VD, AS, VB, DB
glr-7 Glutamate receptor, ionotropic, kainate 3, isoform CRA_a I3, I2, I6, MI, NSM, I1
try-10 Chymotrypsin-like elastase family member 1 Amphids and phasmids
nhr-178 Isoform 2 of Nuclear receptor subfamily 2 group C member 1 Amphids and phasmids
acs-2 Long-chain fatty acid acyl-CoA ligase Several neurons
uvt-6 Somatostatin receptor type 4 Head and tail neurons
T04C9.1 Rho GTPase-activating protein 10 Head and tail neurons
tub-1 Isoform 1 of Tubby protein homolog ASI, ADL, ASK, AWB, ASH, 
ASJ, PHA and PHB and PDE
bbs-1 Isoform 2 of Bardet-Biedl syndrome 1 protein Head and tail neurons and  
mid-body PDEAitlhadj et al.
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and LRRK-2 in cellular functions. Samann 
et al. (2009) demonstrated that mutations in 
both genes suppress the phenotypic effects 
observed in the respective single mutants. 
Furthermore, parkin (pdr-1) deletion caused 
reduced levels of high-molecular-weight 
ubiquitin conjugates. This represents the first 
in vivo evidence that loss of a parkin homolog 
affects the ubiquitin proteasome system 
(UPS), effects that could not be observed in 
the mouse and Drosophila models (Ved et al. 
2005). The UPS is the major route through 
which intracellular proteolysis is regulated. 
Reduced levels of ubiquitin have also been 
observed in obese patients (Chang et al. 
2009), thus lending support to the notion 
that features of neurodegeneration are appar-
ent in the obese. Taken together, these studies 
demonstrate that neurotoxicity studies at the 
genetic level in C. elegans are tremendously 
valuable in deciphering mechanisms that 
underlie mammalian DAergic degeneration.
The dopaminergic system. DA and nor-
epinephrine are monoamine neurotransmitters 
and are derived from tyrosine. In mammals, 
DA is produced by the conversion of the 
amino acid, tyrosine, to 1-dihydroxyphenyl-
alanine (l-DOPA), a reaction mediated by 
TH, followed by l-DOPA metabolism to DA 
by the aromatic amino acid decarboxylase 
(AADC). Cytosolic DA is rapidly packaged 
into synaptic vesicles by a vesicular mono-
amine transporter (VMAT), where DA is 
stored and secreted upon neuronal depolariza-
tion. After exocytosis to the synaptic cleft, DA 
binds to its pre- and postsynaptic receptors 
(D1–D5). The DAergic signal is terminated by 
presynaptic reuptake, which is mediated by the 
dopamine transporter (DAT), followed by its 
inactivation by monoamine oxidase (MAO) or 
the catechol-O-methyl transferase. In a parallel 
pathway, DA can also be converted to nor-
epinephrine by DOPA β-hydroxylase, which 
binds to the adrenergic receptors α1, β1, and 
β2. The norepinephrine signal is terminated 
by presynaptic reuptake, which is mediated by 
the norepinephrine transporter, followed by 
inactivation by MAO.
DA modulates movement, defecation, 
egg laying, and food sensation in the worm 
(Schafer and Kenyon 1995; Weinshenker 
et al. 1995). It was initially detected by means 
of formaldehyde-induced fluorescence in eight 
sensory neurons of the hermaphrodite adult: 
four cephalic (CEP) neurons, two anterior 
deirid (ADE), and two posterior deirid (PDE) 
neurons (Sulston et al. 1975) (Figure 2). 
Additional neurons were noted in the male 
nematode, specifically in six rays of the male 
tail, referred to as the R5A, R7A, and R9A 
pairs of neurons. All of these neurons are 
believed to be mechanosensory, and the abla-
tion of these cells causes defects in the ability 
of the animal to sense or respond to environ-
mental changes (Duerr et al. 1999; Hills et al. 
2004; Sawin et al. 2000). The presence of 
DA, including its precursors and metabolites, 
has been confirmed in C. elegans extracts by 
chromatography and spectroscopy (Wintle 
and Van Tol 2001), demonstrating that DA 
levels in synaptic vesicles are remarkably simi-
lar to those in mammalian neurons (Rand 
et al. 1998). Furthermore, the full requisite 
machinery for DA synthesis, storage, release, 
transport, and binding in C. elegans has been 
uncovered and systematically characterized 
(McDonald et al. 2006; Weinshenker et al. 
1995; Wintle and Van Tol 2001). Given the 
parallels in DAergic homeostasis between 
C. elegans and mammals, the nematode has 
proved an invaluable model system for under-
standing human diseases that implicate abnor-
malities in DAergic function.
C. elegans forward genetics have high-
lighted several genes that encode proteins 
associated with DAergic function. The first 
DA-related loss-of-function mutation identi-
fied affected cat-1, a gene with 47% and 49% 
homology to human VMAT-1 and VMAT-2, 
respectively (Duerr et al. 1999). Cat-2 is the 
C. elegans homolog of mammalian TH, and 
it is expressed in all DAergic neurons, as 
demon  strated by a GFP construct fused to the 
cat-2 promoter (Lints and Emmons 1999). 
An aromatic AADC homolog (bas-1) has also 
been reported as an ortholog of the human 
guanine triphosphate (GTP) cyclohydrolase I 
gene, which, in mammalian systems, expresses 
a protein involved in the regulation of TH 
activity, namely C. elegans cat-4 (Loer and 
Kenyon 1993). Furthermore, DA receptor 
genes have been identified as four mammalian 
homologs, dop-1, dop-2, dop-3, and dop-4 
(Chase and Koelle 2007). Finally, the DAT-1 
transporter has been charac  terized using both 
genetic and pharmacological approaches 
(Jayanthi et al. 1998).
Neurodegeneration by toxic chemicals. 
Most animal models for DAergic neuro-
degeneration are based on exposure to the 
neurotoxins 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and 6-hydroxy-
dopamine (6-OHDA), which chemically 
ablate DAergic neurons (Gerlach and Riederer 
1996; Glinka et al. 1997). 6-OHDA and 
the reactive metabolite of MPTP, MPP+ 
(1-methyl-4-phenylpyridinium), selectively 
accumulate in DAergic neurons, causing   
increased reactive oxygen species (ROS) 
genera  tion and/or mitochondrial dysfunction, 
thereby inducing neuronal damage and cell 
death (Glinka et al. 1997; Javitch et al. 1985).
As in mammals, exposure to 6-OHDA 
causes specific degeneration of DAergic neu-
rons in C. elegans, as revealed by the dose-
dependent decrease in the fluorescence 
signal in the Pdat-1::GFP strain and also by 
the observation of pathological changes in 
TEM worm sections (Nass et al. 2002). The 
C. elegans platform has been highly instru-
mental in establishing that the presence of 
DAT-1 expression is essential for 6-OHDA–
induced DAergic toxicity, as loss of dat-1 
(ok157) function renders the DAergic neu-
rons insensitive to 6-OHDA (Nass et al. 
2002). Interestingly, the 6-OHDA model has 
been successfully used in screens to identify 
not only genetic but also pharmacological 
suppressors of DAergic toxicity. The human 
DAT-1 antagonists imipramine, nisoxetine, 
and amphetamine, as well as the DA receptor 
antagonists bromocriptine, quinpirole, ran-
clopride, and SCH23390, have been shown 
to effectively protect against 6-OHDA neuro-
toxicity in C. elegans. These findings have 
established a valid rationale for future studies 
with these compounds to further elucidate 
their potential therapeutic modalities for the 
treatment of PD in humans (Marvanova and 
Nichols 2007; Nass et al. 2002). Hyperphagia 
Figure 2. Pdat­1: GFP (green fluorescent protein) expression in the DAergic head neurons in C. elegans. 
Bar scale represents 50 µM.An invertebrate model for obesity and Parkinson’s disease
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and obesity can be induced experimentally in 
rodents by the microinjection of 6-OHDA 
into the ventral noradrenergic bundle to 
interrupt efferent catecholaminergic path-
ways to the hypothalamus. This interruption 
is thought to be due to decreased leptin and 
increased neuropeptide Y signaling (Kalra 
et al. 1998).
MPTP is highly lipophilic and read-
ily crosses the mammalian blood–brain bar-
rier and cell membranes. Intracellularly, it 
is metabolized to the active toxic metabolite 
MPP+. This polar molecule is secreted via the 
extraneural monoamine transporter (Russ 
et al. 1996) and actively taken up by DAergic 
cells via DA transporters (Javitch et al. 1985). 
In the mitochondria of DAergic neurons, 
MPP+ inactivates complex I of the respiratory 
chain (Mizuno et al. 1988), decreasing ATP 
levels and increasing free radical production, 
thus leading to DAergic neuro  degeneration. 
Likewise, C. elegans treated with MPTP/
MPP+ respond by significantly reducing 
mobility, which is associated with the specific 
degenera  tion of DAergic neurons (Braungart 
et al. 2004). Analogous to the findings with 
6-OHDA (Nass et al. 2002), MPP+-induced 
DAergic neurodegeneration in C. elegans 
appears to be a caspase-independent cell death 
pathway, suggesting that caspase inhibitors 
may not be effective in rescuing DA neurons 
from cell death (Pu and Le 2008). It has also 
been reported that the loss of function of 
vha-12, a gene involved in necrosis-mediated 
neuro  degeneration that is also expressed in 
DAergic neurons, leads to a hyposensitivity of 
C. elegans to MPP+, suggesting that this neuro-
toxin also triggers the activation of necrotic 
cell death pathways (Pu and Le 2008). Vha-12 
is predicted to bind ATP; therefore, the conse-
quences of MPP+ hyposensitivity could result 
in an altered energy homeostasis, an effect that 
would have implications for obesity.
In addition to chemical exposure, heavy 
metal exposure can cause neurodegeneration. 
Using a specific fluorescent marker to label the 
AFD sensory neuron (Pgcy-8::GFP) revealed 
that Hg, copper (Cu), silver, and chromium 
cause a reduction in the relative intensities of 
cell bodies in AFD neurons, which regulate 
feeding via serotonin and tyramine signaling 
(Figure 1). Metals such as manganese (Mn) 
(Aschner et al. 2007; Benedetto et al. 2009; 
Guilarte 2010), vanadium (Afeseh Ngwa et al. 
2009; Avila-Costa et al. 2004), and Cu (Wang 
et al. 2009; Wimalasena et al. 2007; Yu et al. 
2008), as well as pesticides such as paraquat 
(Andersen 2003) and rotenone (Ishiguro et al. 
2001) and bacterial toxins such as epoxomi-
cin and lactacystin (McNaught et al. 2004; 
Schapira et al. 2006; Zeng et al. 2006) are 
all able to alter optimal DAergic function in 
mammals. The mechanism(s) that underlie 
the neurotoxicity of these toxicants involve 
mitochondrial dysfunction in DA-producing 
neurons, associated with energy depletion, 
increased ROS production, and cell death by 
apoptotic and/or necrotic pathways (Benedetto 
et al. 2009; Ishiguro et al. 2001; Lotharius et al. 
1999). These are the same pathways thought to 
play a role in the neurodegeneration observed 
in obesity.
Mn is an essential trace metal necessary for 
normal brain development and for the optimal 
functioning of multiple enzymes, including 
Mn-superoxide dismutase and glutamine 
synthase (Brock and Walker 1980; Takeda 
and Avila 1986; Wedler and Denman 1984). 
Nevertheless, high levels of exposure to Mn in 
human occupational cohorts (mining, smelting, 
etc.) and in patients with cirrhosis undergoing 
total parenteral nutrition, have been shown to 
cause extrapyramidal symptoms that include 
rigidity, tremor, dystonic movements, and 
brady  kinesia (Aschner et al. 2007; Dobson et al. 
2004; Erikson et al. 2007). Researchers have 
demonstrated that Mn targets DA-rich areas 
in the brain, particularly in the basal ganglia 
(Aschner et al. 2007; Au et al. 2008). Mn can 
readily oxidize DA, thus generating the reactive 
metabolite leukoaminochrome o-semiquinone,   
which is highly toxic to DAergic neurons 
(Díaz-Véliz et al. 2004; Graumann et al. 
2002). Nevertheless, despite the plethora of 
studies in mammalian models (Aschner et al. 
2007; Burton and Guilarte 2009; Dobson 
et al. 2004), much of the insight on its prefer-
ential uptake and targeting of DAergic neurons 
has been derived from studies in C. elegans. 
For example, it has been shown only recently 
that the presence of DA is a requi  site for the 
Mn-induced neuro  degeneration of DAergic 
neurons in vivo. Making use of various genetic 
strains of C. elegans in conjunction with the 
fluorescent tagging of different classes of   
neuron types, Benedetto et al. (2010) demon-
strated that Mn causes a dose-dependent   
degeneration of DAergic neurons. This effect 
was specific to DAergic and absent from 
GABAergic, serotononergic, or glutamatergic 
neurons. Furthermore, Mn was shown to cause 
the significant shortening or disappearance of 
DAergic neuronal extensions at low levels of 
exposure and eventually neuronal death, which 
was characterized by shrinkage of the cell body 
and the complete loss of GFP in Pdat-1::GFP 
worms at higher levels of Mn exposure. A novel 
finding in the C. elegans model was that the 
Mn-induced DAergic degeneration required 
the presence of the reuptake transporter 
DAT-1, as dat-1 loss of function abolished the 
Mn-induced DAergic GFP-fluorescence loss in 
the dat-1; Pdat-1::GFP worms (Benedetto et al. 
2010). Conversely, animals lacking DAT-1 
showed higher susceptibility to Mn toxicity 
than any other homo  zygous mutant tested, 
as observed with MPP+ exposure (Pu and Le 
2008), suggesting that tissues other than those 
of the DAergic system were affected. This is 
consistent with a recent finding in mammals, 
which indicates that norepinephrine plays an 
important role in PD (Rommelfanger and 
Weinshenker 2007). Interestingly, Mn toxicity 
was shown to be prevented by the loss of TH/
CAT-2 function in the double knockout strain, 
cat-2(e1112); dat-1(ok157), establishing that 
DA synthesis is required for DAT-1–dependent 
Mn-induced toxicity. It was further demon-
strated that the absence of VMAT2/CAT-1 in 
cat-1(e1111) mutants, where DAergic neurons 
are unable to release DA at the synaptic cleft, 
resulted in an increased tolerance to Mn expo-
sure, indicating that extracellular DA, but not 
intracellular DA, is involved in Mn toxicity. 
Corroborating this finding, the loss of func-
tion of the three DA receptors led to increased 
extracellular DA, which exacerbated Mn toxic-
ity (Benedetto et al. 2010). These results were 
consistent with the extracellular Mn-induced 
oxidation of synaptic DA-generating ROS, 
as indicated by the increased fluorescence of 
the 2´7´-dichlorodihydrofluorescein diacetate 
probe and the increased cellular lipid oxidation 
inferred from variations in isoprostane levels 
(Benedetto et al. 2010).
Finally, additional experiments uncov-
ered two more antagonistic mediators of the 
Mn-induced DA and DAT-1–dependent 
toxicity, namely, the dual oxidase BLI-3, an 
extracellular enzyme involved in the dityrosine 
cross-linking of collagen for cuticle formation 
in the worm, and SKN-1, the ortholog of the 
mammalian NRF-2 (nuclear factor-2 erythroid 
2-related factor-2) responsible for the regu-
lation of the expression of antioxidants (An and 
Blackwell 2003). The bli-3(e767) mutant strain 
exhibited hyperresistance to Mn exposure and 
failed to show any increase in ROS levels upon 
increasing levels of Mn exposure, and the com-
bined exposure to Mn and exogenous DA did 
not affect the sensitivity of the worms to Mn, 
all results that have not been shown to occur 
in wild-type worms. These observations sug-
gest that this dual oxidase mediates, at least 
partially, the Mn-induced and DA-dependent 
DAergic neurodegenera  tion. Conversely, skn-1 
mutants displayed increased sensitivity, while 
SKN-1 over  expressing worms were found to 
be hyperresistant to Mn exposure; further, 
SKN-1::GFP revealed an Mn-induced change 
in the nuclear localization of SKN-1 in the 
ASI pair of neurons (Benedetto et al. 2010), 
which are involved in the regulation of aging 
in C. elegans (An and Blackwell 2003; Tullet 
et al. 2008).
The sensitivity of DAergic neurons in 
C. elegans to Mn exposure is also reflected by 
the presence of Mn-specific homologs to the 
mammalian NRAMP/divalent metal trans-
porter (DMT), referred to in the nematode 
as SMF. Translational GFP fusions for the 
three transporter isoforms, SMF-1, SMF-2, Aitlhadj et al.
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and SMF-3, revealed tissue-specific localiza-
tions of these transporters in the worm. SMF-1 
and SMF-3 localize in the intestinal epithe-
lium, whereas SMF-2 localizes in the pharyn-
geal epithelium, suggesting different roles for 
these transporters in relation to Mn uptake 
(Au et al. 2009). Furthermore, SMF-1 and 
SMF-2 were found to be expressed ex vivo in 
C. elegans DAT-1–expressing neurons, and 
the deletion of the smf-1 gene attenuated the 
DAergic neurodegeneration caused by Mn 
(Settivari et al. 2009). Moreover, the loss of 
function of smf-1 and smf-3 caused a signifi-
cant decrease in Mn accumulation and conse-
quent increased survival after exposure to the 
metal, establishing that Mn uptake and toxicity 
via DMTs are conserved from nematodes to 
humans (Au et al. 2009). Taken together, Mn 
studies in C. elegans demonstrate that a single 
acute treatment at the first larval stage led to 
both developmental and aging defects, provid-
ing a link between early acute metal exposure, 
neurodegeneration, and longevity.
It has been proposed that environmental 
exposure during initial periods of the neural 
development may increase the susceptibil-
ity of the central nervous system to further 
exposures or increase the risk of developing 
neurodegenerative disorders, such as PD 
(Cory-Slechta et al. 2005). The short life span 
of C. elegans makes it a valuable model for 
exerting toxic insults early on during develop-
ment and allowing the observation of effects 
within a short time span.
Conclusions
The abundance of chemicals and heavy metals 
in the environment has led to human expo-
sure via water, food, and air. Many of these 
substances are able to cross the blood–brain 
barrier, thus presenting a neurotoxic threat. 
Several neurodegenerative diseases have become 
more prevalent because of the increasing aging 
population. Therefore, neuro  toxic poisoning is 
likely to co-occur with age-associated neuro-
degenerative diseases, with each condition 
potentially exacerbating the other. We have 
used the example of PD as an age-associated 
neurodegenerative disease because the inci-
dence for PD increases rapidly in the popula-
tion cohort exceeding 50 years of age. Although 
the precise etiology of the vast majority of PD 
cases remains elusive, there is evidence to show 
that heavy metals and toxic chemicals such 
as cadmium and paraquat can induce both 
the dopaminergic and nor  adrenergic neuronal 
degeneration characteristic of PD. However, 
environmental toxins have also been implicated 
in a wide range of other diseases, including obe-
sity. As obesity is an epidemic that is ultimately 
regulated by the central nervous system, it is 
conceivable that environmental toxins act via 
mechanisms similar or identical to those in PD. 
For example, neurons affected by neurotoxins 
in PD contain DA and nor  epinephrine, both 
of which also play a role in the regulation of 
obesity. In addition, mitochondria are cen-
tral to metabolism and represent a target to 
several environmental toxins that appear to 
contribute to the development of PD and obe-
sity in response to environ  mental toxins by 
inducing apoptosis. The mitochondrial struc-
ture and function in C. elegans are similar to 
their mammalian counterparts, with many of 
the nuclear and mitochondrial encoded genes 
being highly conserved. A plethora of literature 
exists describing the role of serotonin in the 
regulation of both feeding and fat. However, 
relatively few studies have been carried out 
regarding the other neuro  transmitters, largely 
because their role has emerged only recently. 
Deciphering the intricate interplay of neu-
ronal control and degenerative diseases and 
obesity is a complex and multifaceted process. 
Genes do not work in isolation to generate par-
ticular phenotypes; rather, they interact with 
other genes and are influenced by the environ-
ment; therefore, using whole-animal inverte-
brate models such as C. elegans have proved 
to be particularly useful in these ongoing and 
important endeavors. One caveat of using an 
evolutionary distant soil invertebrate to model 
human disease is the notion that nematodes, 
like earthworms, are soil-dwelling organisms 
and thus it is conceivable that selection pressure 
(due to direct exposure to soil pollution) may 
have resulted in the rapid evolution of (dis-
tinct) toxicological response pathways (Hughes 
et al. 2009; Stürzenbaum et al. 2001, 2009; 
Zeitoun-Ghandour et al. 2010). However, 
even though some obstacles remain, the asso-
ciation between neurodegeneration in both PD 
and obesity, with a potential link to environ-
mental toxins, is evident and highly relevant. 
The power of this simple worm to be predic-
tive of mammalian systems has already resulted 
in the identification of many genes shown to 
be important in the etiology of various disease 
models and shows promise as an invaluable 
tool for medium and high-throughput toxico-
logical screening. If forthcoming information 
is extrapolated correctly, the humble worm can 
teach us valuable lessons.
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